1227068-84-9

Basic information

• Product Name: 2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane
• Synonyms: 2-(4,4-difluorocyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane;4,4-Difluorocyclohex-1-enylboronic acid pinacol ester;4,4-difluorocyclohexyl boronic ester;2-(4,4-difluorocyclohex-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;4,4-Difluorocyclohexene-1-boronic Acid Pinacol Ester;(4,4-DIFLUOROCYCLOHEX-1-EN-1-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 1227068-84-9
• Molecular Formula: C₁₂H₁₉BF₂O₂
• Molecular Weight: 244.0858664
• Product Categories: Organic boronic acid
• Mol File: 1227068-84-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 233.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(1227068-84-9)
• EPA Substance Registry System: 2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(1227068-84-9)

Safety Data

• Hazardous Substances Data: 1227068-84-9(Hazardous Substances Data)

Usage

Description

2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is a chemical compound characterized by its unique structure, which features a cyclohexenyl group with two fluorine atoms, a tetramethyl-1,3,2-dioxaborolane moiety, and a double bond in the cyclohexenyl ring. 2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is known for its potential applications in various industries due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a reagent for the preparation of 4-(cycloalkanyloxy)benzenesulfonamide derivatives. These derivatives act as inhibitors of voltage-gated sodium channels, which play a crucial role in the prevention and treatment of various types of pain. By targeting these channels, the compound can help alleviate pain and provide relief to patients suffering from chronic or acute pain conditions.

Upstream product

• 1227068-83-8 trifluoromethane sulfonic acid 4,4-difluorocyclohex-1-en-1-yl ester 
• 73183-34-3 bis(pinacol)diborane 
• 22515-18-0 4,4-difluorocyclohexanone 

Relevant articles and documents

PYRIDAZINONE DERIVATIVE

Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system diseases; and a medicine containing the pyridazinone derivative and/or the pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In the formula, M1 represents a saturated or partially unsaturated C4-12 carbocyclic group or the like; R1 and R2 independently represent a hydrogen atom or the like; M2 represents a group represented by formula (2a) or the like; X1a, X1b and X1c independently represent N or the like; X2, X3 and X4 independently represent CR3 or the like; A1 and A2 independently represent N or the like; and R3 represents a hydrogen atom or the like.]

KIF18A INHIBITORS

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.